Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label retreatment with daclatasvir, asunaprevir, peginterferon alfa-2a, and ribavirin in chronic hepatitis C
NL-OMON39047Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of daclatasvir, asunaprevir, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: SVR12 in genotype 1 prior non-responders. Started Jan 2013; status: active, not recruiting.
02
Drugs
daclatasvirasunaprevirpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON39047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39047.